Updated on 24 April 2013
Although the Indian vaccine sector is plagued with regulatory hurdles, it has a substantial pipeline to look forward to
The Indian vaccine industry has been in the past few years following close on the footsteps of the Indian pharma sector. The vaccine industry has been making concerted efforts to develop vaccines for not only tropical neglected diseases, but also cheaper versions of vaccines that are already available in the West.
The enthusiasm that the vaccine sector has generated was evident at the recently organized Vaccine World Summit 2013 in Pune, India. The event, which proved to be a melting pot of vaccine industry experts, clinicians, regulators, funding agencies and research scientists, saw a large number of foreign agencies seeking to partner with Indian firms. Interestingly, majority of these firms were early stage technology platforms, who were involved in the development of vaccines.
Dr Suresh Jadhav, executive director, Serum Institute of India, very simply put the importance of Indian companies in context, when he said, "Around 75-to-80 percent of vaccines developed and procured by UN agencies are from the developing world and almost 80 percent of these are from India."
Dr T S Rao, adviser, Department of Biotechnology (DBT), India, highlighted that the vaccine industry is worth $260 million and this is slated to reach $500 million, according to consultancy firm McKinsey. These facts reinstate the belief that the Indian vaccine industry has a substantial impact on global immunization, and will continue to be of significance in the days for providing affordable quality vaccines to the world.
However, despite the several achievements, the sector is faced with obstacles. The dearth of a single window clearance is one of the major challenges that the vaccine industry faces in India. The continued delays in procuring permission for trials has affected not only companies but also medical professionals, who conduct trials for gaining a better understanding of the need and effect of vaccines for the Indian population. Mr Sai Prasad, VP, business development, Bharat Biotech, echoed this sentiment. He said, "The development of vaccines involves not one, but a number of government agencies. There are processes that need to be streamlined for the developing newer vaccines so that simple yet important things such as importing specific cell lines, is doable within a defined time limit."